Sarepta治疗 SRPT 深 沪
等待开盘 11-19 09:30:00 美东时间
17.44
-0.100
-0.57%
华盛通- 最 高17.7318
- 今 开17.38
- 成交量 371.79万股
- 最 低 16.94
- 昨 收 17.54
- 总市值 17.04亿
- 52周最高 132.65
- 市盈率 静 7.46
- 换手率 3.80%
- 52周最低 10.415
- 委 比 -76.11%
- 总股本 9771.34万
- 历史最高 181.83
- 量 比 0.76
- 振 幅 4.51%
- 历史最低 0.433
- 每 手 1
- 风险率 42.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sarepta gene therapy Elevidys gets FDA Boxed Warning following two patient deaths
The US FDA has ordered a Boxed Warning be added to the labeling of Sarepta Therapeutics' (SRPT) Elevidys (delandistrogene moxeparvovec) about the risk of fatal acute liver failure for the gene therapy...
11-15 05:24
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
11-12 01:35
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
Sarepta raised to Outperform at Mizuho on strong results
Sarepta Therapeutics (SRPT) upgraded to Outperform from Neutral at Mizuho, citing stronger confidence in the commercial uptake of Elevidys following impressive third-quarter performance. The stock is ...
11-06 02:10
Why Is Dynatrace Stock Gaining Wednesday?
DT reported Q2 earnings that beat estimates, driven by demand for observability tools. ARR and subscription revenue rose.
11-05 21:44
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance
Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevidys sales weakness.
11-05 01:33
Baird Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $15
Baird analyst Brian Skorney maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $21 to $15.
11-05 01:22
Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It
Enough though Sarepta shares are crashing, "Pharma Bro" Martin Shkreli says he still likes the stock.
11-05 01:11
Sarepta Therapeutics (SRPT) Gets a Sell from H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor reiterated a Sell rating on Sarepta The...
11-04 21:37
